# PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

> **NCT06419621** · PHASE3 · RECRUITING · sponsor: **Biotheus Inc.** · enrollment: 360 (estimated)

## Conditions studied

- Triple Negative Breast Cancer(TNBC)

## Interventions

- **DRUG:** PM8002
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06419621
- **Lead sponsor:** Biotheus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2027-07
- **Final completion:** 2028-07
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06419621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06419621, "PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06419621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*